Abstract
As modulators of gene expression, microRNAs (miRNAs) are essential for normal development. Not surprisingly, aberrant expression of miRNAs is associated with many diseases, including cancer. Studies of various breast cancer subtypes have demonstrated that, like gene expression profiles and pathological differences, miRNA profiles can distinguish various tumor subtypes. Over the last few years, roles for miRNAs during many stages of breast cancer progression have been established. This includes potential breast cancer associated polymorphisms in miRNA target sites or miRNAs themselves, miRNAs that can act as tumor suppressors or oncogenes, and miRNAs that can modulate metastatic spread. Recent studies have also suggested key roles for miRNAs in regulating cancer stem cells. Thus, miRNAs have now become important therapeutic targets. This can be achieved by replacing miRNA expression where it has been lost or decreased, or conversely by inhibiting miRNA expression where it has been amplified or overexpressed in cancers. Ultimately, miRNAs should provide both important prognostic biomarkers as well as new targetable molecules for the treatment of breast cancer.
Keywords: Breast cancer, miRNA, novel therapeutics, stem cells
Current Drug Targets
Title: Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression
Volume: 11 Issue: 9
Author(s): Stephanie B. Greene, Jason I. Herschkowitz and Jeffrey M. Rosen
Affiliation:
Keywords: Breast cancer, miRNA, novel therapeutics, stem cells
Abstract: As modulators of gene expression, microRNAs (miRNAs) are essential for normal development. Not surprisingly, aberrant expression of miRNAs is associated with many diseases, including cancer. Studies of various breast cancer subtypes have demonstrated that, like gene expression profiles and pathological differences, miRNA profiles can distinguish various tumor subtypes. Over the last few years, roles for miRNAs during many stages of breast cancer progression have been established. This includes potential breast cancer associated polymorphisms in miRNA target sites or miRNAs themselves, miRNAs that can act as tumor suppressors or oncogenes, and miRNAs that can modulate metastatic spread. Recent studies have also suggested key roles for miRNAs in regulating cancer stem cells. Thus, miRNAs have now become important therapeutic targets. This can be achieved by replacing miRNA expression where it has been lost or decreased, or conversely by inhibiting miRNA expression where it has been amplified or overexpressed in cancers. Ultimately, miRNAs should provide both important prognostic biomarkers as well as new targetable molecules for the treatment of breast cancer.
Export Options
About this article
Cite this article as:
B. Greene Stephanie, I. Herschkowitz Jason and M. Rosen Jeffrey, Small Players With Big Roles: MicroRNAs as Targets to Inhibit Breast Cancer Progression, Current Drug Targets 2010; 11 (9) . https://dx.doi.org/10.2174/138945010792006762
DOI https://dx.doi.org/10.2174/138945010792006762 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IL-2 Receptor Targeted Immunomodulatory Biologics: The Past, Present, and Future
Current Immunology Reviews (Discontinued) Lectins as Ligands for Directing Nanostructured Systems
Current Drug Delivery Identification of Novel Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma using Bioinformatics Analysis
Combinatorial Chemistry & High Throughput Screening Patent Selections
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Is α7-nAChR a Possible Target for Lung Cancer and Malignant Pleural Mesothelioma Treatment?
Current Drug Targets Potential Approaches for Beta Cell Imaging with PET and SPECT
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Gastrin-Releasing Peptide as a Molecular Target for Inflammatory Diseases: An Update
Inflammation & Allergy - Drug Targets (Discontinued) Cubosomes: Versatile Nanosized Formulation for Efficient Delivery of Therapeutics
Current Drug Delivery Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities
Current Pharmaceutical Design Interactions between Transporters and Herbal Medicines/Drugs: A Focus on Hepatoprotective Compounds
Current Drug Metabolism State of the Art on Carbonic Anhydrase Modulators for Biomedical Purposes
Current Medicinal Chemistry Editorial [Hot Topic: Targeting Mast Cells and Basophils in Allergy and Beyond: Emerging Concepts (Executive Guest Editor: Petr Heneberg)]
Current Pharmaceutical Design AMPK As A Target in Rare Diseases
Current Drug Targets Advances in the Development of Class I Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Topics in Medicinal Chemistry Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Drugging Cell Cycle Kinases in Cancer Therapy
Current Drug Targets Chemical Diversity of Grape Products, a Complex Blend of Bioactive Secondary Metabolites
The Natural Products Journal Recent Progress in Biomedical Applications of Magnetic Nanoparticles
Recent Patents on Nanotechnology An Overview of Natural Plant Products in the Treatment of Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry The Significance of COX-2 and COX-2 Inhibitors in Liver Fibrosis and Liver Cancer
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents